Clinical Trial Update: A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating talquetamab and teclistamab, each in combination with a PD-1 inhibitor, for relapsed or refractory multiple myeloma; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• PD-1 inhibitor
• Talquetamab (talquetamab)
• Teclistamab (teclistamab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Relapsed/ Refractory Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING